CRISPR Therapeutics
Gene-based medicines for patients with serious diseases
Total raised
€115M
€115,181,818
Funding rounds
3
Investors
12
distinct backers
Active since
2014-03
latest 2016-05
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood15
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood24
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
- ▲ €100M+ raised
- ▲ 13y since founding
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2016-06-01 | Series B | €35M | Clough Capital Partners,Franklin Templeton Investments,New Leaf Venture Partners,Wellington Management | View deal → |
| 2015-04-01 | Series B | €58M | Abingworth LLP,Bayer Global Investments,Celgene,GlaxoSmithKline,New Enterprise Associates,SR One+2 more | View deal → |
| 2014-04-01 | Series A | €23M | Versant Ventures | View deal → |
Investors
12Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy